Literature DB >> 22230567

Designed ankyrin repeat proteins (DARPins) from research to therapy.

Rastislav Tamaskovic1, Manuel Simon, Nikolas Stefan, Martin Schwill, Andreas Plückthun.   

Abstract

Designed ankyrin repeat proteins (DARPins) have been developed into a robust and versatile scaffold for binding proteins. High-affinity binders are routinely selected by ribosome display and phage display. DARPins have entered clinical trials and have found numerous uses in research, due to their high stability and robust folding, allowing many new molecular formats. We summarize the DARPin properties and highlight some biomedical applications. Protocols are given for labeling with dyes and polyethylene glycol, for quantitatively measuring binding to cell surface receptors by kinetics and thermodynamics, and for exploiting new engineering opportunities from using "click chemistry" with nonnatural amino acids.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22230567     DOI: 10.1016/B978-0-12-396962-0.00005-7

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  51 in total

1.  Bioengineering of bacteria to assemble custom-made polyester affinity resins.

Authors:  Iain D Hay; Jinping Du; Natalie Burr; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2014-10-24       Impact factor: 4.792

2.  Affinity determination of biomolecules: a kinetic model for the analysis of pre-equilibrium titration curves.

Authors:  Emilie Vanhove; Marc Vanhove
Journal:  Eur Biophys J       Date:  2018-07-10       Impact factor: 1.733

Review 3.  Protein-Catalyzed Capture Agents.

Authors:  Heather D Agnew; Matthew B Coppock; Matthew N Idso; Bert T Lai; JingXin Liang; Amy M McCarthy-Torrens; Carmen M Warren; James R Heath
Journal:  Chem Rev       Date:  2019-03-06       Impact factor: 60.622

4.  Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Authors:  Birgit Dreier; Annemarie Honegger; Christian Hess; Gabriela Nagy-Davidescu; Peer R E Mittl; Markus G Grütter; Natalya Belousova; Galina Mikheeva; Victor Krasnykh; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

5.  Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.

Authors:  Martin Schwill; Rastislav Tamaskovic; Aaron S Gajadhar; Florian Kast; Forest M White; Andreas Plückthun
Journal:  Sci Signal       Date:  2019-01-22       Impact factor: 8.192

Review 6.  Protein modeling: what happened to the "protein structure gap"?

Authors:  Torsten Schwede
Journal:  Structure       Date:  2013-09-03       Impact factor: 5.006

7.  Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.

Authors:  Warachai Praditwongwan; Phimonphan Chuankhayan; Somphot Saoin; Tanchanok Wisitponchai; Vannajan Sanghiran Lee; Sawitree Nangola; Saw See Hong; Philippe Minard; Pierre Boulanger; Chun-Jung Chen; Chatchai Tayapiwatana
Journal:  J Comput Aided Mol Des       Date:  2014-07-05       Impact factor: 3.686

Review 8.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

10.  Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.

Authors:  Ashwini Balakrishnan; Anusha Rajan; Alexander I Salter; Paula L Kosasih; Qian Wu; Jenna Voutsinas; Michael C Jensen; Andreas Plückthun; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.